Objectives:To investigate the clinical efficacy and safety of two different regimens in the treatment of cervical cancer stage Ⅱ-Ⅳ.Methods:Retrospective analysis was done on the clinical data of 90 patients with stage Ⅱ-Ⅳ cervical cancer in our hospital from September 2012 to September 2015.According to the random number table method,all patients were divided into two groups,group A and group B,with 45 cases in each group.Group A was treated with three-dimensional conformal radiotherapy combined with paclitaxel + nedaplatin + yew IMRT,and group B was treated with conventional radiotherapy paclitaxel + nedaplatin.Adverse reactions were compared between the two groups.The clinical curative effect,2-year survival rate and adverse reaction were compared.Results:After treatment,the effective rate of group A was 95.55％,which was significantly higher than that of group B (82.22％,P ＜0.05);the 2-year survival rate of group A was 80％,which was significantly higher than that of group B (60.00％,P ＜0.05);there were 13 cases of diarrhea,28 cases of leukopenia,21 cases of nausea and vomiting and 20 cases of loss of appetite in group A.In group B,there were 23 cases of diarrhea,36 cases of leukopenia,34 cases of nausea and vomiting and 31 cases of loss of appetite.Adverse reaction rate in group A was significantly lower,with statistically significant difference (P ＜ 0.05).Conclusion:Three-dimensional conformal radiotherapy combined with paclitaxel and nedaplatin in intensity-modulated radiotherapy has high clinical curative effect and survival rate,with low incidence of adverse reaction,high safety,and high clinical value,which is worthy of promotion and application.%目的:探讨两种方案治疗Ⅱ～Ⅳ期宫颈癌临床疗效和安全性差异.方法:回顾性分析我院2012年9月至2015年9月接诊的90例Ⅱ～Ⅳ期宫颈癌患者的临床资料,按照随机数表法,将所有患者均分为两组,即A组和B组,每组患者均有45例患者,A组采用三维适形放疗联合紫杉醇+奈达铂调强放疗,B组采用紫杉醇+奈达铂常规放疗,比较两组不同的治疗方案临床疗效、患者2年生存率以及药物的不良反应情况.结果:A组治疗后的有效率为95.6％,显著高于B组的82.2％ (P＜0.05);A组治疗后的2年生存率为80.0％,显著高于B组的60.0％ (P ＜0.05);A组出现腹泻13例、白细胞降低28例、恶心呕吐21例以及食欲不振20例,B组分别出现23、36、34以及31例,A组的不良反应发生率明显更低(P＜0.05).结论:三维适形放疗联合紫杉醇+奈达铂调强放疗,其临床疗效和生存率都高,紫杉醇+奈达铂调强放疗后的药物不良反应发生率较低,安全性更高,临床价值较高,值得推广应用.
展开▼
